Column: Trump taps Kodak (yes, that Kodak) to bring stability to the drug market

More than a few people likely were left scratching their heads when President Trump announced this week that the federal government will loan Eastman Kodak $765 million in taxpayer money to develop ingredients for generic drugs.

Kodak? The camera company? The producer of Kodachrome film, which Paul Simon adored for making you think all the world’s a sunny day?

Yes, that Kodak, the same 20th-century photography giant that failed to transition to a 21st-century era of digital cameras (even though it invented the darned things in 1975). The same Kodak that filed for bankruptcy protection in 2012.

“It was one of the great brands in the world,” Trump acknowledged during a press conference to announce the move. “Then people went digital, and Kodak didn’t follow.”

Even so, he said Kodak now will use “advanced manufacturing techniques” to produce drug ingredients “in a manner that is both cost-competitive and environmentally safe.”

The company eventually will produce as much as a quarter of all active ingredients needed for generic drugs taken by Americans, Trump said.

This is one of those rare examples where I find myself in agreement with the president, at least conceptually.

The issue he’s trying to address is a serious one. The vast majority of active ingredients for prescription drugs come from China and India.

Acetaminophen, for example, is America’s most widely used drug ingredient, found not just in namesake pills but also as a component of hundreds of cold, flu and allergy remedies. Nearly all of the world’s supply of it comes from China and India, with China accounting for roughly two-thirds of the total.

If the international pharmaceutical supply chain becomes disrupted — as happened earlier this year when the COVID-19 pandemic erupted — that could severely impact Americans’ access to many prescription drugs.

So Trump is correct to sound a note of alarm that the United States is vulnerable to production (and political) issues abroad.

Most large-scale manufacturing has departed this country, never to return. Auto parts, electronics, shoes, toys, clothing — pick virtually any manufacturing industry.

Chances are, the core components, if not the finished product, are produced overseas by workers paid just pennies on the dollar compared to what an American worker would make.

It’s a given, therefore, that the undeniable benefits of domestic production — more jobs, better quality — come with a trade-off, and that’s higher consumer prices.

William Comanor, a professor of health policy and management at UCLA, told me the average cost of a generic prescription in this country, with at least some ingredients manufactured abroad, is currently $26.

He’s basically asking Americans if they’d be willing to pay 35% more on average for many generic meds in return for the peace of mind that comes with greater control over production.

That may strike some people as a good deal. For most people who struggle to keep healthcare costs under control, though, it may be asking a lot.

And where do we draw the line? There was a time when all TV sets were produced in the United States. Now there are none.

Would you be willing to pay significantly more for that wall-mounted flat screen if at least some of its production could be done domestically? Would you pay more for a car if its parts were manufactured here rather than Mexico?

“That’s exactly the right point,” Comanor acknowledged. “Personally, I say bring generics home and leave auto parts abroad.”

Geoffrey Joyce, chairman of the Department of Pharmaceutical and Health Economics at the USC School of Pharmacy, said, “Kodak’s cost structure is likely to be substantially higher than overseas producers.

“It’s natural to suspect this is a jobs program given the choice of Kodak, a teetering company,” he observed.

“That’s a very good question, one that I’m not sure I have a good answer for,” replied Richard Frank, a professor of health economics at Harvard Medical School.

Kodak owned the drug company Sterling Winthrop from 1988 to 1994, but it produced over-the-counter remedies such as aspirin, not more complicated prescription medicines.

Kodak’s executive chairman, Jim Continenza, said Kodak will utilize its “vast infrastructure, deep expertise in chemicals manufacturing, and heritage of innovation and quality” to help restore “a reliable American pharmaceutical supply chain.”

Um, OK. Except Kodak reported a first-quarter loss of $111 million pursuing business opportunities that it supposedly knows well, such as printers.

After the massive loan from the Trump administration was revealed, giving the company a quarter-century to repay the money, Kodak’s stock soared by almost 2,000%.

Worth noting: Among the drugs Kodak initially will focus on will be hydroxychloroquine, the malaria drug that Trump has repeatedly pushed as a coronavirus treatment but that scientists say can cause harm.

Harvard’s Frank said that while increased domestic drug production may be prudent from a national-security perspective, tapping a company with no pharmaceutical experience as your backstop doesn’t make a lot of sense.

“There’s a lot more to it than just knowing chemical engineering,” he said. “You need to know the suppliers. You need to know the regulatory structure. You need to know the distribution network.”

Anirban Basu, a professor of health economics at the University of Washington, said it’s hard to understand why drug companies would purchase higher-priced ingredients from Kodak, “unless the government puts out a regulation forcing them to do so.”

As such, the federal government can throw as much cash as it pleases at domestic manufacturing.

American consumers are accustomed to prices for manufactured goods that reflect their cut-rate international roots — and few if any pharmaceutical CEOs would buck that trend, even for the most patriotic of reasons.

I agree with Trump that it would be great if we could introduce more security to the drug pipeline.

As with his dream of revitalizing the coal industry, however, this may be an ambition that’s well past its sell-by date.

Get our Boiling Point newsletter for the latest on the power sector, water wars and more — and what they mean for California.

You may occasionally receive promotional content from the Los Angeles Times.

David Lazarus is an award-winning business columnist for the Los Angeles Times. He also appears daily on KTLA Channel 5. His work runs in newspapers across the country and has resulted in a variety of laws protecting consumers.

Politics

Coronavirus-induced 32.9% collapse in GDP is one for the record books

Politics

Coronavirus-induced 32.9% collapse in GDP is one for the record books

Hot Property

Scenic homes for $800,000 in Santa Barbara County

Hot Property

Scenic homes for $800,000 in Santa Barbara County

Take a look at homes with a view for around $800,000 in Lompoc, Santa Barbara and Santa Maria in Santa Barbara County.

Business

Free drinks, store credit and cries for help: How we’re handling the coin shortage

Business

Free drinks, store credit and cries for help: How we’re handling the coin shortage

Many stores are asking customers to use exact change, credit or debit cards. But there are other workarounds.

California

Newsom announces ‘strike team’ for California’s unemployment agency as 1 million await benefits

California

Newsom announces ‘strike team’ for California’s unemployment agency as 1 million await benefits

Many people who lost jobs or income in California due to coronavirus say they have been unable to get the benefits for which they are eligible.

California

Less stress, better grades: With schools closed, some kids thrive

California

Less stress, better grades: With schools closed, some kids thrive

When the pandemic caused schools to shutter, some students relished more free time, less-stressful classes and a lack of bullying.

World & Nation

‘We’ve let our guard down’: Europe battles to contain new coronavirus surge

World & Nation

‘We’ve let our guard down’: Europe battles to contain new coronavirus surge

After weathering what they thought was the worst of the COVID-19 crisis, European countries are seeing new spikes in infections as restrictions ease.

California

Health crisis looming inside a health crisis: People are avoiding going to the doctor

California

Health crisis looming inside a health crisis: People are avoiding going to the doctor

Americans are avoiding hospitals and clinics, even when they shouldn’t be. Experts expect a jump in preventable diseases after the pandemic eases.

Lifestyle

Full bladders, closed bathrooms. Strategies for peeing while out during coronavirus

Lifestyle

Full bladders, closed bathrooms. Strategies for peeing while out during coronavirus

Travelers are finding many public restrooms closed these days, due to the pandemic. Here’s what you need to know about finding a place to go when you’re on the go.

Lifestyle

Your friend is throwing a party during a pandemic. How do you say no?

Lifestyle

Your friend is throwing a party during a pandemic. How do you say no?

How to politely turn down an invitation to socialize while there’s still a pandemic going on.

Food

Almost 30 million Americans didn’t have enough to eat last week

Food

Almost 30 million Americans didn’t have enough to eat last week

Food insecurity for U.S. households last week reached its highest reported level since the Census Bureau started tracking the data in May, with almost 30 million Americans reporting that they’d not had enough to eat at some point in the seven days through July 21.

Hot Property

‘L.A. Confidential’ house seeks $7.495 million in Hancock Park

Hot Property

‘L.A. Confidential’ house seeks $7.495 million in Hancock Park

In Hancock Park, a 1920s Spanish-style home that starred in the film “L.A. Confidential” just came to market at $7.495 million.

Business

Wall Street rallies as Fed keeps rates pinned at record low

Business

Wall Street rallies as Fed keeps rates pinned at record low

Wall Street rallied on Wednesday, and the S&P 500 climbed 1.2% for its best day in two weeks after the Federal Reserve kept the accelerator floored on its support for the economy.

Business

Congress members think $600 is too much to pay workers. Here’s what the lawmakers get

Business

Congress members think $600 is too much to pay workers. Here’s what the lawmakers get

How to compare the $600 weekly that Congress thinks is too lavish to the $3,346 the lawmakers receive

Business

Fed sees dim economic outlook as virus squeezes economy

Business

Fed sees dim economic outlook as virus squeezes economy

The Federal Reserve expressed concern Wednesday that the persistent viral outbreak will act as a drag on the economy and hiring in the coming months and said it plans to keep its benchmark short-term interest rate pegged near zero to help provide support.

Source: https://www.latimes.com/business/story/2020-07-30/column-kodak-drug-ingredients

Kodak

World news – NG – Column: Trump taps Kodak (yes, that Kodak) to bring stability to the drug market

Leave a Reply

Your email address will not be published. Required fields are marked *